About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The aim of our group is to investigate the use of medicines and evaluate its benefit/risk relationship in usual clinical practice. Our group coordinates the Catalan centre of the Spanish System of Pharmacovigilance. Research activities on pharmacology and pharmacoepidemiology are coupled with undergraduate teaching at the Autonomous University of Barcelona Medical School, training of specialists in clinical pharmacology, and continuous education of health professionals on therapeutics.
The group is a Special Group of Research recognized by AGAUR GenCat. It is a partner of “The European Consortium “EU PE&PV Network” (European Pharmacoepidemiology and Pharmacovigilance Network)” and it is part of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). It gives institutional support to the Clinical Research Ethical Committee of the University hospital Vall d’Hebron (UHVH), the Drug and Pharmacotherapeutic Committee of the UHVH, and also to the Drug and Pharmacotherapeutic Committee of the Institut Català de la Salut.
PMID: 36583998 Journal: PLoS One Year: 2022 Reference: PLoS One. 2022 Dec 30;17(12):e0279333. doi: 10.1371/journal.pone.0279333. eCollection 2022. Impact factor: Publication type: Paper in international publication Authors: Alfonso, Fernando; Amat-Santos, Ignacio J; Angiolillo, Dominick J; Arevalos, Victor; Baneras, Jordi; Bastidas, Gabriela; Bikdeli, Behnood; Brugaletta, Salvatore; Campo, Gianluca; de la Torre Hernandez, Jose M et al. DOI: 10.1371/journal.pone.0279333
PMID: 35114859 Journal: ANNALS OF MEDICINE Year: 2022 Reference: Ann Med. 2022 Dec;54(1):379-392. doi: 10.1080/07853890.2021.2016940. Impact factor: 4.709 Publication type: Paper in international publication Authors: Figueiras, Adolfo; Salgado, Angel; Mallah, Narmeen; Zapata-Cachafeiro, Maruxa; Aguirre, Carmelo; Ibarra-Garcia, Eguzkine; Palacios-Zabalza, Itziar; Macias-Garcia, Fernando; Pineiro-Lamas, Maria; Ibanez, Luisa et al. DOI: 10.1080/07853890.2021.2016940
PMID: 33846003 Journal: MEDICINA CLINICA Year: 2022 Reference: Med Clin (Barc). 2022 Feb 11;158(3):111-117. doi: 10.1016/j.medcli.2020.12.041. Epub 2021 Apr 9. Impact factor: 1.725 Publication type: Paper in national publication Authors: Crespo-Fresno, Almudena; Vidal-Guitart, Xavier; Sanchez-Raya, Judith; Pages-Bolibar, Esther; Cuxart-Fina, Ampar et al. DOI: 10.1016/j.medcli.2020.12.041
PMID: 35127085 Journal: Molecular and clinical oncology Year: 2022 Reference: Mol Clin Oncol. 2022 Mar;16(3):60. doi: 10.3892/mco.2022.2493. Epub 2022 Jan 12. Impact factor: 0 Publication type: Letter or abstract Authors: Hernando, Jorge; Riera-Arnau, Judit; Roca, Maria; Garcia, Alejandro; Capdevila, Jaume et al. DOI: 10.3892/mco.2022.2493
PMID: 33170306 Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY Year: 2021 Reference: Eur J Clin Pharmacol. 2021 Apr;77(4):637-642. doi: 10.1007/s00228-020-03033-5. Epub 2020 Nov 10. Impact factor: Publication type: Paper in international publication Authors: Alvarado Aguirre, L A; Cereza Garcia, G; Figueras, A; Garcia Dolade, N; Riera-Arnau, J; Vidal Guitart, X et al. DOI: 10.1007/s00228-020-03033-5
PMID: 33627229 Journal: MEDICINA CLINICA Year: 2021 Reference: Med Clin (Barc). 2021 Jun 11;156(11):568-572. doi: 10.1016/j.medcli.2021.01.009. Epub 2021 Feb 21. Impact factor: Publication type: Paper in national publication Authors: Aguilera, Cristina; Guillen, Elena; Sans-Pola, Carla et al. DOI: 10.1016/j.medcli.2021.01.009
PMID: 32538681 Journal: Multiple Sclerosis Journal Year: 2021 Reference: Mult Scler. 2021 Mar;27(3):475-478. doi: 10.1177/1352458520929628. Epub 2020 Jun 15. Impact factor: Publication type: Paper in international publication Authors: Addor, Marie-Claude; Agusti, Antonia; Baud, David; Buclin, Thierry; Cottin, Judith; Diav-Citrin, Orna; Kadioglu, Mine; Kaplan, Yusuf C; Kennedy, Debra; Livio, Francoise et al. DOI: 10.1177/1352458520929628
PMID: 33037766 Journal: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY Year: 2021 Reference: Basic Clin Pharmacol Toxicol. 2021 Mar;128(3):440-454. doi: 10.1111/bcpt.13517. Epub 2020 Nov 2. Impact factor: Publication type: Paper in international publication Authors: Aakjaer, M; Aakjaer, M; Andersen, M; Andersen, M; Ballarin, E; Ballarin, E; de Bruin, M; De Bruin, M L; Droz, C; Gardarsdottir, H et al. DOI: 10.1111/bcpt.13517
The results show the need for continuous monitoring of patients to detect and manage possible adverse effects occurring months and years after treatment.
The creation of hybrid digital-human interaction spaces between avatars and people offers new opportunities for personalized medicine
The study by physician Emilie Anderssen seeks to optimize the medicalization of people living in nursing homes.
